论文部分内容阅读
肺动脉高压是一种有着高发病率和死亡率的渐进性肺血管疾病。有明显证据表明受体酪氨酸激酶,如血小板衍生生长因子(platelet-derived growth factor,PDGF)与肺动脉高压发病机制密切相关。该研究调查2种新型PDGF抑制剂:尼洛替尼/AMN107(Abl激酶/PDGF受体抑制剂)和达沙替尼/BMS-354825(Abl激酶/PDGF受体/Src抑制剂)对肺动脉平滑肌细胞(pulmonary arterial smooth muscle cells,PASMC)增殖和迁移、实验性肺动脉高压血流动力学和肺血管重塑的作用,
Pulmonary hypertension is a progressive pulmonary vascular disease with high morbidity and mortality. There is clear evidence that receptor tyrosine kinases, such as platelet-derived growth factor (PDGF), are closely linked to the pathogenesis of pulmonary hypertension. The study investigated the effects of two new PDGF inhibitors, nilotinib / AMN107 (Abl kinase / PDGF receptor inhibitor) and dasatinib / BMS-354825 (Abl kinase / PDGF receptor / Src inhibitor) on pulmonary artery smooth muscle Proliferation and migration of pulmonary arterial smooth muscle cells (PASMC), experimental pulmonary hypertension and pulmonary vascular remodeling,